Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH EBITDA Margin
EBITDA as a percentage of revenue.
Accendra Health, Inc.NYSE: ACH
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 8.9%
EBITDA Margin was 8.9% in Q1 FY2026, up 6.6 pp from a year earlier. On a trailing-twelve-month basis it was 12.7%, up 12.2 pp year over year. Over 3 fiscal years it widened by 9.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 12.9% for the fiscal year ending Dec 2026, down from 13.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 8.9%-3.4 pp QoQ
- Last fiscal yearDec 2025
- 13.2%+12.7 pp YoY
- LTMMar 2026
- 12.7%+12.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.6 pp | -1.0 pp | -7.6 pp |
| 1 year | +12.7 pp | -0.3 pp | -13.0 pp |
| 3 years | +9.5 pp | -1.7 pp | -11.2 pp |
| 5 years | -0.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 13.2%
- Year-over-year change
- +12.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.2% | +12.7pp |
| FY2024 | 2024-12-31 | 0.5% | -3.3pp |
| FY2023 | 2023-12-31 | 3.8% | +0.1pp |
| FY2022 | 2022-12-31 | 3.7% | -0.5pp |
| FY2021 | 2021-12-31 | 4.2% | — |
EBITDA Margin vs competitors
How ACH compares with its peers on the latest reported figures
- ACH's LTM Mar 2026 EBITDA Margin of 12.7% is the highest of the 9 companies compared; the peer median is -71.8%.
- Its year-over-year change of +12.2 pp is the 6th highest of 9, against a peer median of +16.3 pp.
- Over three fiscal years its change of +9.5 pp compares with a peer median of +80.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 12.7% | +12.2 pp | +9.5 pp | |
| LTM Apr 2026 | -0.9% | -5.9 pp | +7.1 pp | |
| LTM Mar 2026 | -39.8% | +16.3 pp | +70.4 pp | |
| LTM Mar 2026 | -53.0% | +16.3 pp | +80.2 pp | |
| LTM Mar 2026 | -65.7% | +112.4 pp | +874.7 pp | |
| LTM Mar 2026 | -77.8% | +9.1 pp | +98.8 pp | |
| LTM Mar 2026 | -258.7% | +387.8 pp | +719.4 pp | |
| LTM Mar 2026 | -843.9% | -542.0 pp | -540.2 pp | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -864.8% | +3922.9 pp | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ACH) | -71.8% | +16.3 pp | +80.2 pp | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.79B | 9.96B | 10.33B | 10.7B | 2.76B |
| Cost of Revenue | 8.27B | 8.13B | 8.21B | 8.48B | 1.56B |
| Gross Profit | 1.51B | 1.83B | 2.13B | 2.22B | 1.2B |
| Gross Margin | 15.5% | 18.3% | 20.6% | 20.7% | 43.5% |
| Research & Development | 12.1M | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.08B | 1.55B | 1.81B | 1.91B | 1.05B |
| Operating Expenses | 1.14B | 1.68B | 2.02B | 2.43B | 1.05B |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| EBITDA | 415.47M | 368.45M | 390.57M | 51.22M | 364.68M |
| EBITDA Margin | 4.2% | 3.7% | 3.8% | 0.5% | 13.2% |
| Operating Income | 368.47M | 142.91M | 104.51M | (207.77M) | 150.16M |
| Operating Margin | 3.8% | 1.4% | 1.0% | -1.9% | 5.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 48.09M | 128.89M | 157.92M | 143.8M | 129.2M |
| Other Income / Expenses | (91.72M) | (132.02M) | (159.23M) | (149.59M) | (252.11M) |
| Income Before Tax | 276.75M | 10.89M | (54.73M) | (357.36M) | (101.95M) |
| Pre-Tax Margin | 2.8% | 0.1% | -0.5% | -3.3% | -3.7% |
| Income Tax Expense | 55.17M | (11.5M) | (13.43M) | 5.33M | 729K |
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (1.1B) |
| Net Margin | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% |
| EPS (Basic) | 3.05 | 0.30 | (0.54) | (4.73) | (14.31) |
| EPS (Diluted) | 2.94 | 0.29 | (0.54) | (4.73) | (14.31) |
| Weighted Avg Shares | 72.74M | 74.5M | 75.79M | 76.74M | 76.9M |
| Weighted Avg Shares (Diluted) | 75.49M | 76.22M | 75.79M | 76.74M | 76.9M |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.